两种定量粪便免疫化学检测在结直肠癌筛查项目中检测进展期肿瘤的准确性相当
在荷兰国家结直肠癌筛查项目中开展大型前瞻性队列研究,随机选取42179名55至75岁筛查初筛对象,要求同一份粪便完成FOB-Gold与OC-Sensor两种定量粪便免疫化学检测,任一阳性(≥15 μg血红蛋白/克粪便)者接受结肠镜检查。结果显示两种检测对进展期肿瘤的检出率绝对差为0.01%(95%CI -0.06%至0.08%),在预设0.15%等效界值内判定为准确性相当。
要点
- FOB-Gold检出进展期肿瘤610人(1.45%),OC-Sensor检出606人(1.44%),绝对差0.01%(95%CI -0.06%至0.08%)。
- 两种检测阳性率分别为7.5%(1582/21078)与7.7%(1627/21078),差异P=.140。
- FOB-Gold相对OC-Sensor检出进展期肿瘤的真实阳性率比为0.97(95%CI 0.92-1.01),结直肠癌为0.95(95%CI 0.87-1.03)。
核心结论
- 在荷兰大型前瞻性筛查研究中,FOB-Gold与OC-Sensor两种定量粪便免疫化学检测对进展期肿瘤的检测准确性相当。
研究设计与样本
- 荷兰国家结直肠癌筛查项目内的大型前瞻性队列研究,2016年5月至2017年3月随机选取42179名55至75岁筛查初筛对象。
- 参与者用同一份粪便自行完成FOB-Gold(Sentinel,米兰,意大利)与OC-Sensor(Eiken Chemical,东京,日本)两种定量检测,任一或两项阳性(≥15 μg血红蛋白/克粪便)者接受结肠镜检查作为参考标准。
- 等效性以预设界值0.15%评估,荷兰国家试验注册号NTR5874。
主要发现
- 42179名受邀者中22064人(52%)参与,21078人完成两种检测。
- 2112名(9.6%)检测阳性者中1778人(84%)接受结肠镜检查。
- 全部受邀者中,FOB-Gold检出经结肠镜确认的进展期肿瘤610人(1.45%),OC-Sensor检出606人(1.44%),绝对差0.01%(95%CI -0.06%至0.08%)。
- 完成两种检测的21078人中,FOB-Gold阳性1582人(7.5%),OC-Sensor阳性1627人(7.7%),P=.140。
- FOB-Gold相对OC-Sensor检出进展期肿瘤的真实阳性率比为0.97(95%CI 0.92-1.01),结直肠癌为0.95(95%CI 0.87-1.03);进展期肿瘤的假阳性率比为0.99(95%CI 0.93-1.05)。
关键数值与推荐
- 阳性阈值定义为≥15 μg血红蛋白/克粪便,任一检测阳性即邀请结肠镜检查。
- 等效性预设界值为0.15%。
临床怎么用
- 作者认为该结果对全球结直肠癌筛查项目选择粪便免疫化学检测具有参考意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Although different brands of fecal immunochemical tests (FITs) are used for colorectal cancer (CRC) screening, few studies have compared their accuracy in detecting advanced neoplasia. METHODS: We performed a large prospective cohort study within the Dutch national CRC screening program to evaluate 2 quantitative FITs: FOB-Gold (Sentinel, Milan, Italy) and OC-Sensor (Eiken Chemical, Tokyo Japan), from May 2016 through March 2017. We randomly selected 42,179 screening-naïve individuals (55-75 years old), who were asked to perform both FITs themselves using the same bowel movement. Participants with positive results from 1 or both FITs (≥15 μg hemoglobin/gram feces) were invited for colonoscopy examination (reference standard). Equivalence in detection of advanced neoplasia was evaluated with a predefined margin of 0.15%. RESULTS: Of 42,179 invitees, 22,064 (52%) participated and FITs were completed for 21,078 participants. Of 2112 participants (9.6%) with 1 or 2 positive results from FITs, 1778 (84%) underwent a colonoscopy. Of all invitees, the FOB-Gold test detected advanced neoplasia (confirmed by colonoscopy) in 610 participants (1.45%) and the OC-Sensor detected advanced neoplasia (confirmed by colonoscopy) in 606 participants (1.44%)-an absolute difference of 0.01% (95% confidence interval [CI], -0.06% to 0.08%). Of the 21,078 participants who completed both FITs, 1582 (7.5%) had a positive result from the FOB-Gold test and 1627 (7.7%) a positive result from the OC-Sensor test (P = .140). The relative true-positive rate of FOB-Gold vs OC-Sensor in detecting advanced neoplasia was 0.97 (95% CI, 0.92-1.01) and 0.95 (95% CI, 0.87-1.03) for CRC. The relative false-positive rate of the FOB-Gold test vs the OC-Sensor test in detecting advanced neoplasia was 0.99 (95% CI, 0.93-1.05). CONCLUSIONS: In a large prospective study of individuals invited for CRC screening in The Netherlands, we found equivalent accuracy of the FOB-Gold FIT vs the OC-Sensor FIT in detecting advanced neoplasia. These results are relevant for selecting FITs for CRC screening programs worldwide. Dutch National Trial Registry: NTR5874.
引用
- Wieten E, de Klerk CM, van der Steen A, et al. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program. Gastroenterology. 2018. PMID: 30055170. doi:10.1053/j.gastro.2018.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。